Table 1 Clinicopathologic characteristics of the patients in the training set and validation sets
|  | Training set (n = 313) | Validation set 1 (n = 95) | Validation set 2 (n = 201) | Validation set 3 (n = 83) |
|---|---|---|---|---|
Age, Median (IQR), y | 63 (56–72) | 63 (55–72) | 64 (57–71) | 63 (56–70) |
Sex | Â | Â | Â | Â |
 Male | 261 (83.4%) | 78 (82.1%) | 167 (83.1%) | 70 (84.3%) |
 Female | 52 (16.6%) | 17 (17.9%) | 34 (16.9%) | 13 (15.7%) |
T stage | Â | Â | Â | Â |
 Ta | 19 (6.1%) | 3 (3.2%) | 13 (6.5%) | 10 (12.0%) |
 T1 | 207 (66.1%) | 60 (63.2%) | 148 (73.6%) | 52 (62.7%) |
 T2-* | 87 (27.8%) | 32 (33.7%) | 40 (19.9%) | 21 (25.3%) |
Grade | Â | Â | Â | Â |
 Low grade | 90 (28.8%) | 28 (29.5%) | 96 (47.8%) | 35 (42.2%) |
 High grade | 223 (71.2%) | 67 (70.5%) | 105 (52.2%) | 48 (57.8%) |